中文 | English



Linkedbio is the newly launched services provided by Lingmed. We help companies to understand and monitor China market opportunities, define the right strategies and work with the right partners




Linkedbio Report No.179

Lingmed asset recommendation-Noval treatment for anemia in chronic kidney disease and cancer

  • Novel and potent hepcidin antagonist (pegylated protein) with unique mode-of-action compared to erythropoietin stimulating agents, iron and HIF-PH inhibitors
  • Safety profile and dose-dependent effect on serum iron level and transferrin saturation demonstrated in phase Ia
  • Safety profile and dose-dependent effect on serum iron level and transferrin saturation demonstrated in phase Ib in chronic kidney disease patients on hemodialysis
  • Multi-ascending dose 2a clinical trial in chronic kidney disease patients on hemodialysis ongoing


Linkedbio Report No.177

In this month summary, Lingmed recommends

  • Lingmed Indication report- Eye/Ophthalmic disorders
  • The October Financial analysis of global bio-pharmaceuticals market by Biotechgate data analysis team




If you are interested in Lingmed historical achieved reports, please click here





Confirm your details on form below to download this report

Company name *
Your name *
Email *
Phone *
Notes

©Copyright 2013 - 2018 Lingmed Limited